

Multi and Single dose vials as referenced by a US customer vs stability acc to Vandenbroucke et al

Product name	S=Single Dose Vials M=Multi Dose Vials	Stability according to Vandenbroucke	Reference
Herceptin® (trastuzumab)	M	2 days	13
Paclitaxel® (taxol)	M	RTU	
Novantrone® (mitoxantrone)	M	RTU	
DaunoXome® (Daunorubicin)	M	7 days	1
Paraplatin® (carboplatin)	M	RTU	
Etopophos®, Vepesid® (etoposide)	M	RTU	
Mitomycin® (mitomycin-C)	M	14 days	2
Cytosar-U® (cytarabine)	M	RTU	
Velban® (vinblastine)	M	7 days	
Platinol®-AQ (cisplatin)	M	RTU	
Gemcitabine	M	36 days	9
Campath® (alemtuzumab)	S	No data	
Velcade™ (bortezomib)	S	8H	
Taxotere® (docetaxel)	S	28 days	7.8
Hycamtin® (topotecan hydrochloride)	S	17 days	12
Camptosar® (irinotecan)	S	RTU	
Caelyx®, Myocet® (Liposomal Doxorubicin)	S	RTU	
Rituxan® (rituximab)	S	No data	
Navelbine® (vinorelbine)	S	RTU	
Fludara® (fludarabine)	S	14 days	
Eloxatin® 50 mg/5ml (oxauplatin injection)	S	28 days	10
Eloxatin® 100mg/5ml (oxauplatin injection)	S	28 days	10
Oncovin® (vincristine)	S	RTU	
Blenoxan® (bleomycin)	S	28 days	1
Trexall® (methotrexate)	S	RTU	
Alkeran® (melphalan)	S	1H	
Pharmorubicin® (epirubicin)	S	RTU	
Adriamycin® (doxorubicin)	S	RTU	
DTIC-Dome® (dacarbazine)	S	4 days	6
Mitoxana® (ifosfamide)	S	7 days	1
Adrucil® or 5-FU (fluorouracil)	S	RTU	
Alimta® (pemetrexed)	S	3 days	11
Abraxane® (paclitaxel protein-bound particles)	S	No data	
Avastin® (bevacizumab-injection)	S	RTU	
Cytosan® (cyclophosphamide)	S	7 days	5

Disclaimer:

Carmel Pharma accepts no responsibility for the accuracy of information in this publication. It is the users responsibility to ensure that all information is updated and correct.

References from Vandenbroucke et al; EJHP Practice

Volume 14 2008 Issue 5

- Wood MJ, Allwood MC, Oakes JM, et al. Chemotherapeutic agents. In: Allwood M, Stanley A, Wright P, editors. The cytotoxic handbook. 4th ed. Oxford: Radcliffe Medical Press; 2002.
- Trissel LA. Handbook on injectable drugs. 8th ed. Bethesda: American Society of Health-System Pharmacists; 1994.
- B Braun container compatibility database [homepage on the internet]. Melsungen: [cited 2008 April 22]. Available from: www.concomp-partner.com/index.php
- Stabilis international database [homepage on the internet]. Nancy: [cited 2008 April 22]. Available from: www.stabilis.org/Monographie.php?Liste&codeLangue=UK
- Brooke D, Bequette RJ, Davis RE. Chemical stability of cyclophosphamide in parenteral solutions. Am J Hosp Pharm. 1973;30(2):134-7.
- El Aatmani M, Poujol S, Astre C, et al. Stability of dacarbazine in amber glass vials and polyvinyl chloride bags. Am J Health-Syst Pharm. 2002;59(14):1351-6.
- Cytostatica monographies from the oncology workgroup of ADKA. Krankenhauspharmazie. 1999;20(3):97-102.
- Thiesen J, Krämer I. Physico-chemical stability of docetaxel premix solution and docetaxel infusion solutions in PVC bags and polyolefinecontainers. Pharm World Sci. 1999;21(3):137-41.
- Xu Q, Zhang Y, Trissel LA. Physical and chemical stability of gemcitabine hydrochloride solutions. J Am Pharm Assoc. 1999;39(4):509-13.
- Trittler R, Heni J, Strehl E. Studies on stability of oxaliplatin. Krankenhauspharmazie. 2000;21(7):375-6.
- Zhang Y, Trissel LA. Physical and chemical stability of pemetrexed in infusion solutions. Ann Pharmacother. 2006;40:1082-5.
- Krämer I, Thiesen J. Stability of topotecan infusion solutions in polyvinylchloride bags and elastomeric portable infusion devices. J Onc Pharm Pract. 1999;5(2):75-82.
- ABPI Medicines Compendium. Summary of product characteristics for Herceptin. Roche Products Limited. Electronic Medicines Compendium. [cited 2008 April 22]. Available from: www.emc.medicines.org.uk
- Dine T, Luyckx M, Cazin JC, et al. Stability and compatibility studies of vinblastine, vincristine, vindesine and vinorelbine with PVC infusion bags. Int J Pharmaceutics. 1991;77(2-3):279-85.